Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion

MT Newswires Live

06/16

Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.

The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.

Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.

Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.

The company's shares rose 2% in recent Tuesday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2643738679"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2643738679\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2643738679?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643738679","market":"nz","top_or_hot":-1,"title":"Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion","media":"MT Newswires Live","content":"<html><body><p> Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.</p><p>The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.</p><p>Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.</p><p>Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.</p><p>The company's shares rose 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-16 10:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.</p><p>The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.</p><p>Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.</p><p>Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.</p><p>The company's shares rose 2% in recent Tuesday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NYR.AU","symbol_name":"NYRADA INC-CDI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643738679","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643738679","pubTimestamp":1781578431,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nyrada  said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.The company's shares rose 2% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NYR.AU":"NYRADA INC-CDI","BK7096":"制药"},"translate_title":"Nyrada表示心脏病候选药物的2a期试验有望于2027年完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NYR.AU":1},"content_text":"Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.The company's shares rose 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}